GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:000758421 | Liver | HCC | response to nutrient | 111/7958 | 174/18723 | 1.10e-08 | 2.73e-07 | 111 |
GO:000963622 | Liver | HCC | response to toxic substance | 153/7958 | 262/18723 | 1.37e-07 | 2.58e-06 | 153 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
GO:00323552 | Liver | HCC | response to estradiol | 81/7958 | 141/18723 | 2.39e-04 | 1.79e-03 | 81 |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:00459263 | Liver | HCC | negative regulation of growth | 129/7958 | 249/18723 | 1.81e-03 | 9.37e-03 | 129 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC6A4 | SNV | Missense_Mutation | novel | c.428A>G | p.His143Arg | p.H143R | P31645 | protein_coding | tolerated(0.05) | probably_damaging(0.991) | TCGA-37-3792-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | | c.853N>A | p.Ala285Thr | p.A285T | P31645 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-46-6026-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
SLC6A4 | SNV | Missense_Mutation | rs753300083 | c.554N>G | p.Tyr185Cys | p.Y185C | P31645 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-63-A5MH-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | | c.730N>T | p.Gly244Trp | p.G244W | P31645 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-66-2758-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
SLC6A4 | SNV | Missense_Mutation | | c.130N>C | p.Ser44Pro | p.S44P | P31645 | protein_coding | tolerated(0.16) | possibly_damaging(0.583) | TCGA-66-2758-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
SLC6A4 | SNV | Missense_Mutation | novel | c.1574N>A | p.Val525Glu | p.V525E | P31645 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-O2-A5IB-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
SLC6A4 | SNV | Missense_Mutation | novel | c.25N>G | p.Gln9Glu | p.Q9E | P31645 | protein_coding | tolerated_low_confidence(0.67) | benign(0) | TCGA-CN-6013-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
SLC6A4 | SNV | Missense_Mutation | novel | c.1818G>T | p.Glu606Asp | p.E606D | P31645 | protein_coding | tolerated(0.08) | benign(0.066) | TCGA-CR-7379-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | novel | c.1637N>G | p.Pro546Arg | p.P546R | P31645 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CV-6962-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | rs201480140 | c.392C>T | p.Pro131Leu | p.P131L | P31645 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EJ-8474-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 8 | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | DULOXETINE | DULOXETINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | buprenorphine | BUPRENORPHINE | 29333880 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178104007 | LEVOMILNACIPRAN | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | berberine | BERBERINE | 21647174 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178103894 | VENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | DESVENLAFAXINE | DESVENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | ethanol | ALCOHOL | 31595439 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | VENLAFAXINE | VENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | AMOXAPINE | AMOXAPINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | AMOXAPINE | AMOXAPINE | |